Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Genotyping: one piece of the puzzle to personalize antiplatelet therapy.

Gurbel PA, Tantry US, Shuldiner AR, Kereiakes DJ.

J Am Coll Cardiol. 2010 Jul 6;56(2):112-6. doi: 10.1016/j.jacc.2010.04.008. Epub 2010 May 13.

2.

Pharmacogenomics of clopidogrel: evidence and perspectives.

Yin T, Miyata T.

Thromb Res. 2011 Oct;128(4):307-16. doi: 10.1016/j.thromres.2011.04.010. Epub 2011 May 18. Review.

PMID:
21592545
3.

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Valente S, Antoniucci D, Abbate R, Gensini GF.

Pharmacogenet Genomics. 2007 Dec;17(12):1057-64.

PMID:
18004210
4.

Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.

Hochholzer W, Trenk D, Fromm MF, Valina CM, Stratz C, Bestehorn HP, Büttner HJ, Neumann FJ.

J Am Coll Cardiol. 2010 Jun 1;55(22):2427-34. doi: 10.1016/j.jacc.2010.02.031.

5.

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.

Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Büttner HJ, Neumann FJ.

J Am Coll Cardiol. 2008 May 20;51(20):1925-34. doi: 10.1016/j.jacc.2007.12.056.

6.

Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention.

Bonello-Palot N, Armero S, Paganelli F, Mancini J, De Labriolle A, Bonello C, Lévy N, Maillard L, Barragan P, Dignat-George F, Camoin-Jau L, Bonello L.

Am J Cardiol. 2009 Dec 1;104(11):1511-5. doi: 10.1016/j.amjcard.2009.07.015.

PMID:
19932784
7.

Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.

Harmsze A, van Werkum JW, Bouman HJ, Ruven HJ, Breet NJ, Ten Berg JM, Hackeng CM, Tjoeng MM, Klungel OH, de Boer A, Deneer VH.

Pharmacogenet Genomics. 2010 Jan;20(1):18-25. doi: 10.1097/FPC.0b013e328333dafe.

PMID:
19934793
8.

Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis.

Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthélémy O, Cayla G, Beygui F, Montalescot G.

J Am Coll Cardiol. 2010 Jul 6;56(2):134-43. doi: 10.1016/j.jacc.2009.12.071.

9.

The case for routine genotyping in dual-antiplatelet therapy.

Damani SB, Topol EJ.

J Am Coll Cardiol. 2010 Jul 6;56(2):109-11. doi: 10.1016/j.jacc.2010.03.029. Epub 2010 May 13.

10.

Recent advances in the pharmacogenetics of clopidogrel.

Cuisset T, Morange PE, Alessi MC.

Hum Genet. 2012 May;131(5):653-64. doi: 10.1007/s00439-011-1130-6. Epub 2011 Dec 30. Review.

PMID:
22207144
11.

Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.

Frere C, Cuisset T, Morange PE, Quilici J, Camoin-Jau L, Saut N, Faille D, Lambert M, Juhan-Vague I, Bonnet JL, Alessi MC.

Am J Cardiol. 2008 Apr 15;101(8):1088-93. doi: 10.1016/j.amjcard.2007.11.065. Epub 2008 Feb 6.

PMID:
18394438
12.

Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Cavallari U, Trabetti E, Sabaté M, Hernández R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Costa MA, Bass TA, Pignatti PF, Macaya C.

Arterioscler Thromb Vasc Biol. 2006 Aug;26(8):1895-900. Epub 2006 Apr 27.

13.

Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.

Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, Zenni MM, Guzman LA, Bass TA, Costa MA.

Circulation. 2007 Feb 13;115(6):708-16. Epub 2007 Jan 29.

14.

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.

Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, Lachno DR, Salazar D, Winters KJ.

J Thromb Haemost. 2007 Dec;5(12):2429-36. Epub 2007 Sep 26.

15.

Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.

Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Buonamici P, Antoniucci D, Abbate R, Gensini GF.

Am J Cardiol. 2009 Mar 15;103(6):806-11. doi: 10.1016/j.amjcard.2008.11.048. Epub 2009 Jan 24.

PMID:
19268736
16.

Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel.

Ma TK, Lam YY, Tan VP, Kiernan TJ, Yan BP.

Pharmacol Ther. 2010 Feb;125(2):249-59. doi: 10.1016/j.pharmthera.2009.10.008. Epub 2009 Nov 14. Review.

PMID:
19919843
17.

Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement.

Trenk D, Hochholzer W, Frundi D, Stratz C, Valina CM, Bestehorn HP, Büttner HJ, Neumann FJ.

Thromb Haemost. 2008 Jan;99(1):174-81. doi: 10.1160/TH07-08-0503.

PMID:
18217151
18.

Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.

Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P.

Blood. 2006 Oct 1;108(7):2244-7. Epub 2006 Jun 13.

19.

Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.

Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dörrler K, Morath T, Schömig A, Kastrati A, von Beckerath N.

Eur Heart J. 2009 Apr;30(8):916-22. doi: 10.1093/eurheartj/ehp041. Epub 2009 Feb 4.

20.

Personalized antiplatelet therapy: review of the latest clinical evidence.

Camilleri E, Jacquin L, Paganelli F, Bonello L.

Curr Cardiol Rep. 2011 Aug;13(4):296-302. doi: 10.1007/s11886-011-0194-1. Review.

PMID:
21594586
Items per page

Supplemental Content

Write to the Help Desk